| Pharmacotherapy of Zollinger-Ellison syndrome. | |
| | |
MedLine Citation:
|
PMID: 23363383 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Introduction: The role of pharmacotherapy in the management of patients with Zollinger-Ellison syndrome (ZES) is often equated with the medical management of acid hypersecretion. However, pharmacotherapy is also increasingly involved in the other management areas of these patients. Areas covered: This paper reviews the role of pharmacotherapy in all aspects of the management of patients with ZES. Newer aspects are emphasized. This includes the difficulty of diagnosing ZES in patients taking proton pump inhibitors. Also covered is the role of pharmacotherapy in controlling acid hypersecretion and other hormonal hypersecretory states these patients may develop, including hyperparathyroidism in patients with multiple endocrine neoplasia type 1 and ZES; tumor localization; and the treatment of advanced metastatic disease. The last includes chemotherapy, liver-directed therapies, biotherapy (somatostatin/interferon), peptide radio-receptor therapy and molecular-targeted therapies including the use of mTor inhibitors (everolimus) and tyrosine kinase inhibitors (sunitinib). Expert opinion: Pharmacotherapy is now involved in all aspects of the management of patients with ZES, with the result that ZES has progressed from being considered an entirely surgical disease initially to the present where medical treatment plays a major role in almost all aspects of the management of these patients. |
| | |
Authors:
|
Tetsuhide Ito; Hisato Igarashi; Hirotsugu Uehara; Robert T Jensen |
Related Documents
:
|
11977163 - Cerebro-osseous-digital syndrome: four new cases of a lethal skeletal dysplasia--distin... 23439263 - Lessons from look-back in acute liver failure? a single centre experience of 3,300 pati... 1918413 - Cerebrospinal fluid concentration of fibronectin in meningitis. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-30 |
Journal Detail:
|
Title: Expert opinion on pharmacotherapy Volume: - ISSN: 1744-7666 ISO Abbreviation: Expert Opin Pharmacother Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-31 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100897346 Medline TA: Expert Opin Pharmacother Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Kyushu University, Graduate School of Medical Sciences, Department of Medicine and Bioregulatory Science , 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582 , Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: On the cellular and molecular regulatory transcriptional mechanisms and responsive putative pathways...
Next Document: The Biology of Hair Diversity.